Resumo

LANGJAHR, Patricia  e  SOTELO, Pablo H.. Vaccines against chikungunya virus: advances and perspectives. Rev. parag. reumatol. [online]. 2023, vol.9, n.2, pp.71-75.  Epub 30-Dez-2023. ISSN 2413-4341.  https://doi.org/10.18004/rpr/2023.09.02.71.

Chikungunya virus (CHIKV) is an alphavirus that causes an illness characterized mainly by fever and joint/muscle pain. Between 25-50% of infections present with chronic diseases that can last from months to years. The first outbreak of CHIKV in Paraguay occurred in 2015, with the last outbreak occurring in 2022/2023. Several vaccine candidates against CHIKV are in different stages of development, and even recently (November/2023), the first vaccine against CHIKV, called VLA1553 (Ixchiq), was approved. In addition, at least 30 vaccine candidates are available for preclinical and clinical trials. With the approval of the first vaccine against CHIKV and the possibility of others coming to the market soon, due to the advanced status of other vaccine candidates, a new scenario will open for this disease. The introduction of effective vaccines is expected to generate an important advance in the prevention of this disease, reducing acute cases and the chronic effects of viral infection. This review analyzes the progress of CHIKV vaccines and examines the epidemiological surveillance challenges posed by the introduction of these vaccines.

Palavras-chave : alphavirus; chikungunya virus (CHIKV); vaccines; viral vaccines; chikungunya vaccine; vaccine development..

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )